Education Archives - Page 2 of 3 - CRC Minimal Residual Disease

Understanding the Most Common Definition of MRD in Medical Literature
Gallery

Understanding the Most Common Definition of MRD in Medical Literature

Kathryn Aziz2024-07-15T21:36:26+00:00

Giulia Maddalena, a clinical oncologist by education and research trainee at MD Anderson Cancer Center, discusses how medical literature defines MRD and shares your survey results regarding what is your preferred definition. In cancer research, the importance of MRD has been growing, extending its relevance from hematologic malignancies to solid tumors. However, it stands for different definitions according to the specific context: Minimal Residual Disease, Molecular Residual Disease, or Measurable Residual Disease. This variability in terminology reflects the evolving nature of cancer diagnostics and treatment monitoring. Given the importance of clarity in medical terminology, we conducted a literature [...]

Understanding the Most Common Definition of MRD in Medical LiteratureKathryn Aziz2024-07-15T21:36:26+00:00

Study finds promising new blood test for detecting colorectal cancer
Gallery

Study finds promising new blood test for detecting colorectal cancer

Kathryn Aziz2024-04-17T20:19:45+00:00

Health article discussing new blood test developed by Guardant Health that accurately identified colorectal cancer in 83% of patients with confirmed disease by detected circulating tumor DNA (ctDNA).

Study finds promising new blood test for detecting colorectal cancerKathryn Aziz2024-04-17T20:19:45+00:00

2024 ASCO Annual Meeting
Gallery

2024 ASCO Annual Meeting

Kathryn Aziz2024-05-28T18:31:33+00:00

American Society of Clinical Oncology (ASCO) 2024 Annual Meeting is being held Friday, May 31st through Tuesday, June 4th, with numerous scheduled sessions related to minimal residual disease in colorectal cancer. Highlighted Sessions and Posters Use of MRD-Guided Strategies to Optimize Therapeutic Interventions Circulating Biomarkers: Who, What, Where, When, and Why? Gastrointestinal Cancer—Colorectal and Anal Abstracts and Posters Clinical validation of a novel circulating tumor DNA methylation assay for predicting recurrence of colorectal cancer in patients with curative-intent surgery by monitoring minimal residual disease. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined [...]

2024 ASCO Annual MeetingKathryn Aziz2024-05-28T18:31:33+00:00

Cancer Network’s Around the Practice Series “ASCO GI 2024: Updates in MRD Testing for the Management of Colorectal Cancer”
Gallery

Cancer Network’s Around the Practice Series “ASCO GI 2024: Updates in MRD Testing for the Management of Colorectal Cancer”

Kathryn Aziz2024-04-17T19:52:08+00:00

Cancer Network posts 15-episode series "ASCO GI 2024: Updates in MRD Testing for the Management of Colorectal Cancer" in which medical oncologists highlight clinical trials presented at ASCO GI 2024 and discuss the utility of minimal residual disease (MRD) and circulating tumor DNA (ctDNA).

Cancer Network’s Around the Practice Series “ASCO GI 2024: Updates in MRD Testing for the Management of Colorectal Cancer”Kathryn Aziz2024-04-17T19:52:08+00:00

Cancer Network’s Around the Practice Series “ctDNA in Treatment Decisions and Monitoring”
Gallery

Cancer Network’s Around the Practice Series “ctDNA in Treatment Decisions and Monitoring”

Kathryn Aziz2024-04-17T17:15:19+00:00

Cancer Network posts 10-episode series titled "Around the Practice: ctDNA in Treatment Decisions and Monitoring" in which expert oncologists discuss current and future use of minimal residual disease (MRD) and circulating tumor DNA (ctDNA) in colorectal cancer.

Cancer Network’s Around the Practice Series “ctDNA in Treatment Decisions and Monitoring”Kathryn Aziz2024-04-17T17:15:19+00:00

A Patient-in-Waiting : An opinion piece from CRC caregiver on ctDNA Testing
Gallery

A Patient-in-Waiting : An opinion piece from CRC caregiver on ctDNA Testing

Kristin Alfaro2023-11-07T19:28:54+00:00

In the ever-evolving landscape of cancer diagnosis and treatment, scientists and researchers are continually seeking innovative ways to improve patient outcomes. One such breakthrough in the field of oncology is the use of ctDNA (circulating tumor DNA) liquid biopsies. These cutting-edge tests have the potential to revolutionize cancer detection and management, offering hope to patients and healthcare providers alike. A recent article on STAT News, titled "ctDNA Liquid Biopsy: Signatera's Role in Detecting Cancer Recurrence and Minimal Residual Disease," sheds light on the promising advancements in the world of ctDNA testing. This article explores how the Signatera platform is changing [...]

A Patient-in-Waiting : An opinion piece from CRC caregiver on ctDNA TestingKristin Alfaro2023-11-07T19:28:54+00:00

Dr. Sam Klempner discusses the use of circulating tumor DNA (ctDNA) testing to monitor for minimal residual disease (MRD) in GI cancer

Kristin Alfaro2023-09-26T14:46:11+00:00

In this session, Dr Sam Klempner from Massachusetts General Hospital discusses the use of circulating tumor DNA (ctDNA) testing to monitor for minimal residual disease (MRD) in GI cancer. https://youtu.be/HSMwPqhGVxo?si=_z2RUr2gkXmAT8Hj

Dr. Sam Klempner discusses the use of circulating tumor DNA (ctDNA) testing to monitor for minimal residual disease (MRD) in GI cancerKristin Alfaro2023-09-26T14:46:11+00:00

The Changing Landscape of MRD Testing for Colorectal Cancer: What’s New in 2023?

Kristin Alfaro2023-09-26T14:43:38+00:00

In this presentation, the Dr. John Stricker discusses the use of circulating tumor DNA (ctDNA) testing in colorectal cancer patients to guide treatment decisions. The presentation includes discussions on the sensitivity and specificity of ctDNA testing and its potential impact on treatment strategies. Several case studies are presented, highlighting the challenges and considerations when interpreting ctDNA results, especially in the context of adjuvant chemotherapy decisions for stage two colorectal cancer patients. The speaker emphasizes the need for careful evaluation and monitoring of ctDNA status to make informed treatment choices and discusses ongoing research in this area. https://youtu.be/b4qaM-Iqie0?si=RQGWPGvyxGr0dmHw [...]

The Changing Landscape of MRD Testing for Colorectal Cancer: What’s New in 2023?Kristin Alfaro2023-09-26T14:43:38+00:00

The current state of MRD testing in colorectal cancer

Kristin Alfaro2023-09-26T14:27:34+00:00

Afsaneh Barzi, MD, PhD, City of Hope, Duarte, CA, provides an overview of the clinical impact of minimal residual disease (MRD) testing in colorectal cancer, and strategies to optimize sensitivity. False negatives may occur during testing, and there is no definite treatment regimen for patients who are MRD positive post-surgery. MRD testing alone should additionally not determine whether patients should receive adjuvant therapy. Dr Barzi also highlights disparities in the use of MRD testing. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA. These works are owned by [...]

The current state of MRD testing in colorectal cancerKristin Alfaro2023-09-26T14:27:34+00:00

Dr. Y. Nancy You shares what young adults should know about colon cancer.

Kristin Alfaro2023-09-26T14:22:26+00:00

Dr. Y. Nancy You shares what young adults should know about colon cancer. https://youtu.be/Vb8R1bCtCDw?si=nK7kwb9AhAC8Fumf

Dr. Y. Nancy You shares what young adults should know about colon cancer.Kristin Alfaro2023-09-26T14:22:26+00:00

QUICK LINKS

MENU